13. Caputo I, Barone MV, Lepretti M, Martucciello S, Nista I, et al. (2010) Celiac anti-tissue transglutaminase antibodies interfere with the uptake of alpha gliadin peptide 31–43 but not of peptide 57–68 by epithelial cells. Biochim Biophys Acta 1802(9): 717–727. 14. Barone MV, Nanayakkara M, Paolella G, Maglio M, Vitale V, et al. (2010) Gliadin peptide P31–43 localises to endocytic vesicles and interferes with their maturation. PLoS One 5(8): e12246. 15. Siegel M, Strnad P, Watts RE, Choi K, Jabri B, et al. (2008) Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury. PLoS One 3(3): e1861. 16. Nicholas B, Smethurst P, Verderio E, Jones R, Griffin M (2003) Cross-linking of cellular proteins by tissue transglutaminase during necrotic cell death: a mechanism for maintaining tissue integrity. Biochem J 371(2): 413–422. 17. Shin DM, Jeon JH, Kim CW, Cho SY, Kwon JC, et al. (2004) Cell type-specific activation of intracellular transglutaminase 2 by oxidative stress or ultraviolet irradiation: implications of transglutaminase 2 in age-related cataractogeneis. J Biol Chem 279(16): 15032–15039. 18. Luciani A, Villella VR, Vasaturo A, Giardino I, Pettoello-Mantovani M, et al. (2010) Lysosomal accumulation of gliadin p31–43 peptide induces oxidative stress and tissue transglutaminase-mediated PPAR gamma downregulation in intestinal epithelial cells and coeliac mucosa. Gut 59(3): 311–319. 19. Silano M, Di Benedetto R, Trecca A, Arrabito G, Leonardi F, et al. (2007) A decapeptide from durum wheat prevents celiac peripheral blood lymphocytes from activation by gliadin peptides. Pediatr Res 61(1): 67–71. 20. Zimmer KP, Fischer I, Mothes T, Weissen-Plenz G, Schmitz M, et al. (2010) Endocytotic segregation of gliadin peptide 31–49 in enterocytes. Gut 59(3): 300– 310. 21. Secondo A, Staiano RI, Scorziello A, Sirabella R, Boscia F, et al. (2007) BHK cells transfected with NCX3 are more resistant to hypoxia followed by reoxygenation than those transfected with NCX1 and NCX2: Possible relationship with mitochondrial membrane potential. Cell Calcium 42(6): 521– 535. 22. Caputo I, Lepretti M, Secondo A, Martucciello S, Paolella G, et al. (2011) Anti- tissue transglutaminase antibodies activate intracellular tissue transglutaminase by modulating cytosolic Ca(2+) homeostasis. Amino Acids, 2011, DOI: 10.1007/s00726-011-1120-yOnline FirstTM. 23. Esposito C, Paparo F, Caputo I, Porta R, Salvati VM, et al. (2003) Expression and enzymatic activity of small intestinal tissue transglutaminase in celiac disease. Am J Gastroenterol. 98(8):1813–1820. 24. Duchen MR (2000) Mitochondria and Ca(2+) in cell physiology and pathophysiology. Cell Calcium 28(5–6): 339–348. 25. Zhang J, Lesort M, Guttmann RP, Johnson GV (1998) Modulation of the in situ activity of tissue transglutaminase by calcium and GTP. J Biol Chem 23; 273(4): 2288–2295. 26. Lee AS (2001) The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci 26(8): 504–510. 27. Wang XZ, Lawson B, Brewer JW, Zinszner H, Sanjay A, et al. (1996) Signals from the stressed endoplasmic reticulum induce C/EBP-homologous protein (CHOP/GADD153). Mol Cell Biol 16: 4273–4280. 28. Junn E, Ronchetti RD, Quezado MM, Kim SY, Mouradian MM (2003) Tissue transglutaminase-induced aggregation of alpha synuclein: implication for Lewy body formation in Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 100(4): 2047–2052. 29. Bailey CD, Johnson GV (2005) Tissue transglutaminase contributes to disease progression in the R6/2 Huntington’s disease mouse model via aggregate- independent mechanisms. J Neurochem 92(1): 83–92. 30. Chhabra A, Verma A, Mehta K (2009) Tissue transglutaminase promotes or suppresses tumours depending on cell context. Anticancer Res 29(6): 1909–1919. Ca2+ Mobilization Induced by Gliadin 31. Orru` S, Caputo I, D’Amato A, Ruoppolo M, Esposito C (2003) Proteomics identification of acyl-acceptor and acyl-donor substrates for transglutaminase in a human intestinal epithelial cell line. Implications for celiac disease. J Biol Chem 278(34): 31766–31773. 32. Lesort M, Attanavanich K, Zhang J, Johnson GV (1998) Distinct nuclear localization and activity of tissue transglutaminase. J Biol Chem 5;273(20): 11991–11994. 33. Kuo TF, Tatsukawa H, Kojima S (2011) New insights into the functions and localization of nuclear transglutaminase 2. FEBS J 278(24): 4756–4767. 34. McConoughey SJ, Basso M, Niatsetskaya ZV, Sleiman SF, Smirnova NA, et al. (2010) Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington’s disease. EMBO Mol Med 2(9): 349–370. 35. Tatsukawa H, Fukaya Y, Frampton G, Martinez-Fuentes A, Suzuki K, et al. (2009) Role of transglutaminase 2 in liver injury via cross-linking and silencing of trasciption factor Sp1. Gastroenterology 136(5): 1783–95.e10. 36. Singh US, Kunar MT, Kao YL, Baker KM (2001) Role of transglutaminase II in retinoic acid-induced activation of RhoA-associated kinase-2. EMBO J 20(10): 2413–2423. 37. Myrsky E, Caja S, Simon-Vecsei Z, Korponay-Szabo IR, Nadalutti C, et al. (2009) Celiac disease IgA modulates vascular permeability in vitro through the activity of transglutaminase 2 and RhoA. Cell Mol Life Sci 66(20): 3375–3385. 38. Verma A, Mehta K (2007) Transglutaminase-mediated activation of nuclear transcription factor-kappaB in cancer cells: a new therapeutic opportunity. Curr Cancer Drug Targets 7(6): 559–565. 39. Maiuri MC, De Stefano D, Mele G, Fecarotta S, Greco L, et al. (2003) Nuclear factor kappa B is activated in small intestinal mucosa of celiac patients. J Mol Med (Berl) 81(6): 373–379. 40. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, et al. (1998) Nuclear factor kappa B is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115: 357–369. 41. Andresen L, Jørgensen VL, Perner A, Hansen A, Eugen-Olsen J, et al. (2005) Activation of nuclear factor kappa B in colonic mucosa from patients with collagenous and ulcerative colitis. Gut 54(4): 503–509. 42. Bodger K, Halfvarson J, Dodson AR, Campbell F, Wilson S, et al. (2006) Abnormal colonic glycoprotein expression in unaffected monozygotic twins of inflammatory bowel disease patients. Gut 55: 973–977. 43. Simula MP, Cannizzaro R, Canzonieri V, Pavan A, Maiero S, et al. (2010) PPAR signaling pathway and cancer-related proteins are involved in celiac disease-associated tissue damage. Mol Med 16(5–6): 199–209. 44. Orrenius S, Zhivotovsky B, Nicotera P (2003) Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol 4(7): 552–565. 45. McGuckin MA, Eri RD, Das I, Lourie R, Florin TH (2010) ER stress and the unfolded protein response in intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 298(6): G820–832. 46. Zinszner H, Kuroda M, Wang X, Batchvarova N, Lightfoot RT, et al. (1998) CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev 12: 982–995. 47. Park SH, Choi HJ, Yang H, Do KH, Kim J, et al. (2010) Endoplasmic reticulum stress-activated C/EBP homologous protein enhances nuclear factor-kappaB signals via repression of peroxisome proliferator-activated receptor gamma. J Biol Chem 285(46): 35330–35339. 48. Ni M, Lee AS (2007) ER chaperones in mammalian development and human diseases. FEBS 581(19): 3641–3651. 49. Kaser A, Lee AH, Franke A, Glickman JN, Zeissig S, et al. (2008) XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 134(5): 743–756. PLOS ONE | www.plosone.org 12 September 2012 | Volume 7 | Issue 9 | e45209